- Home
- BCAB vs APM Comparison
BCAB vs APM Comparison
Compare BCAB & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BCAB | APM |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1M | 7.3M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BCAB | APM |
|---|---|---|
| Price | $4.38 | $0.85 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 47.5K | 21.0K |
| Earning Date | 05-08-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $300,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $0.65 |
| 52 Week High | $6.52 | $4.47 |
Technical Indicators
Market Signals| Indicator | BCAB | APM |
|---|---|---|
| Relative Strength Index (RSI) | 56.97 | 45.23 |
| Support Level | $0.36 | $0.77 |
| Resistance Level | $6.33 | $0.86 |
| Average True Range (ATR) | 0.59 | 0.07 |
| MACD | -0.22 | -0.01 |
| Stochastic Oscillator | 20.72 | 5.27 |
Price Performance
Historical ComparisonAbout BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.